

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001. Amended 01/01/2011

|                       |                                      |
|-----------------------|--------------------------------------|
| <b>Name of entity</b> | <b>SIGMA PHARMACEUTICALS LIMITED</b> |
| <b>ABN</b>            | <b>ABN 15 088 417 403</b>            |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                       |
|----------------------------|-----------------------|
| <b>Name of Director</b>    | <b>Brian JAMIESON</b> |
| <b>Date of last notice</b> | 21/09/2012            |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |   |
|---|---|
| <b>Direct or indirect interest</b>  | Direct interest                         |
| <b>Nature of indirect interest (including registered holder)</b><br>Note: Provide details of the circumstances giving rise to the relevant interest.                        |   |
| <b>Date of change</b>   | 19/12/2012                              |
| <b>No. of securities held prior to change</b>   | 462,712                                 |
| <b>Class</b>  | FPO                                     |
| <b>Number acquired</b>  | 12,947                                  |
| <b>Number disposed</b>  |   |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | \$9,192.37                              |
| <b>No. of securities held after change</b>  | 475,659                                 |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Shares purchased under NED's Share Plan |

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Detail of contract</b>   |  |
| <b>Nature of interest</b>   |  |
| <b>Name of registered holder<br/>(if issued securities)</b>   |  |
| <b>Date of change</b>   |  |
| <b>No. and class of securities to<br/>which interest related prior to<br/>change</b><br><small>Note: Details are only required for a contract in relation<br/>to which the interest has changed</small> |  |
| <b>Interest acquired</b>  |  |
| <b>Interest disposed</b>  |  |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an<br/>estimated valuation</small>   |  |
| <b>Interest after change</b>  |  |

#### Part 3 – <sup>+</sup>Closed period

|   |    |
|---|----|
| <b>Were the interests in the<br/>securities or contracts detailed<br/>above traded during a <sup>+</sup>closed<br/>period where prior written<br/>clearance was required?</b> | No |
| <b>If so, was prior written clearance<br/>provided to allow the trade to<br/>proceed during this period?</b>  |    |
| <b>If prior written clearance was<br/>provided, on what date was this<br/>provided?</b>   |    |

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001. Amended 01/01/2011

|                       |                                      |
|-----------------------|--------------------------------------|
| <b>Name of entity</b> | <b>SIGMA PHARMACEUTICALS LIMITED</b> |
| <b>ABN</b>            | <b>ABN 15 088 417 403</b>            |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                             |
|----------------------------|-----------------------------|
| <b>Name of Director</b>    | <b>Linda Bardo NICHOLLS</b> |
| <b>Date of last notice</b> | 21/09/2012                  |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |   |
|---|---|
| <b>Direct or indirect interest</b>  | Direct interest                         |
| <b>Nature of indirect interest (including registered holder)</b><br>Note: Provide details of the circumstances giving rise to the relevant interest.                        |   |
| <b>Date of change</b>   | 19/12/2012                              |
| <b>No. of securities held prior to change</b>   | 489,369                                 |
| <b>Class</b>  | FPO                                     |
| <b>Number acquired</b>  | 7,622                                   |
| <b>Number disposed</b>  |   |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | \$5,411.62                              |
| <b>No. of securities held after change</b>  | 496,991                                 |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Shares purchased under NED's Share Plan |

### Part 2 – Change of director's interests in contracts

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Detail of contract</b>   |  |
| <b>Nature of interest</b>   |  |
| <b>Name of registered holder<br/>(if issued securities)</b>   |  |
| <b>Date of change</b>   |  |
| <b>No. and class of securities to<br/>which interest related prior to<br/>change</b><br><small>Note: Details are only required for a contract in relation<br/>to which the interest has changed</small> |  |
| <b>Interest acquired</b>  |  |
| <b>Interest disposed</b>  |  |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an<br/>estimated valuation</small>   |  |
| <b>Interest after change</b>  |  |

#### Part 3 – <sup>+</sup>Closed period

|   |    |
|---|----|
| <b>Were the interests in the<br/>securities or contracts detailed<br/>above traded during a <sup>+</sup>closed<br/>period where prior written<br/>clearance was required?</b> | No |
| <b>If so, was prior written clearance<br/>provided to allow the trade to<br/>proceed during this period?</b>  |    |
| <b>If prior written clearance was<br/>provided, on what date was this<br/>provided?</b>   |    |

*Rule 3.19A.2*

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/2011

|                       |                                      |
|-----------------------|--------------------------------------|
| <b>Name of entity</b> | <b>SIGMA PHARMACEUTICALS LIMITED</b> |
| <b>ABN</b>            | <b>ABN 15 088 417 403</b>            |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                    |
|----------------------------|--------------------|
| <b>Name of Director</b>    | <b>David BAYES</b> |
| <b>Date of last notice</b> | 21/09/2012         |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |   |
|---|---|
| <b>Direct or indirect interest</b>  | Direct interest                         |
| <b>Nature of indirect interest (including registered holder)</b><br>Note: Provide details of the circumstances giving rise to the relevant interest.                        |   |
| <b>Date of change</b>   | 19/12/2012                              |
| <b>No. of securities held prior to change</b>   | 178,294                                 |
| <b>Class</b>  | FPO                                     |
| <b>Number acquired</b>  | 7,915                                   |
| <b>Number disposed</b>  |   |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | \$5,619.65                              |
| <b>No. of securities held after change</b>  | 186,209                                 |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Shares purchased under NED's Share Plan |

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Detail of contract</b>   |  |
| <b>Nature of interest</b>   |  |
| <b>Name of registered holder<br/>(if issued securities)</b>   |  |
| <b>Date of change</b>   |  |
| <b>No. and class of securities to<br/>which interest related prior to<br/>change</b><br><small>Note: Details are only required for a contract in relation<br/>to which the interest has changed</small> |  |
| <b>Interest acquired</b>  |  |
| <b>Interest disposed</b>  |  |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an<br/>estimated valuation</small>   |  |
| <b>Interest after change</b>  |  |

#### Part 3 – <sup>+</sup>Closed period

|   |    |
|---|----|
| <b>Were the interests in the<br/>securities or contracts detailed<br/>above traded during a <sup>+</sup>closed<br/>period where prior written<br/>clearance was required?</b> | No |
| <b>If so, was prior written clearance<br/>provided to allow the trade to<br/>proceed during this period?</b>  |    |
| <b>If prior written clearance was<br/>provided, on what date was this<br/>provided?</b>   |    |

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001. Amended 01/01/2011

|                       |                                      |
|-----------------------|--------------------------------------|
| <b>Name of entity</b> | <b>SIGMA PHARMACEUTICALS LIMITED</b> |
| <b>ABN</b>            | <b>ABN 15 088 417 403</b>            |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                            |
|----------------------------|----------------------------|
| <b>Name of Director</b>    | <b>David Gerald MANUEL</b> |
| <b>Date of last notice</b> | 21/09/2012                 |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |   |
|---|---|
| <b>Direct or indirect interest</b>  | Direct interest                         |
| <b>Nature of indirect interest (including registered holder)</b><br>Note: Provide details of the circumstances giving rise to the relevant interest.                        |   |
| <b>Date of change</b>   | 19/12/2012                              |
| <b>No. of securities held prior to change</b>   | 103,194                                 |
| <b>Class</b>  | FPO                                     |
| <b>Number acquired</b>  | 5,717                                   |
| <b>Number disposed</b>  |   |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | \$4,059.07                              |
| <b>No. of securities held after change</b>  | 108,911                                 |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Shares purchased under NED's Share Plan |

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Detail of contract</b>   |  |
| <b>Nature of interest</b>   |  |
| <b>Name of registered holder<br/>(if issued securities)</b>   |  |
| <b>Date of change</b>   |  |
| <b>No. and class of securities to<br/>which interest related prior to<br/>change</b><br><small>Note: Details are only required for a contract in relation<br/>to which the interest has changed</small> |  |
| <b>Interest acquired</b>  |  |
| <b>Interest disposed</b>  |  |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an<br/>estimated valuation</small>   |  |
| <b>Interest after change</b>  |  |

#### Part 3 – <sup>+</sup>Closed period

|   |    |
|---|----|
| <b>Were the interests in the<br/>securities or contracts detailed<br/>above traded during a <sup>+</sup>closed<br/>period where prior written<br/>clearance was required?</b> | No |
| <b>If so, was prior written clearance<br/>provided to allow the trade to<br/>proceed during this period?</b>  |    |
| <b>If prior written clearance was<br/>provided, on what date was this<br/>provided?</b>   |    |

*Rule 3.19A.2*

---

<sup>+</sup> See chapter 19 for defined terms.



# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/2011

|                       |                                      |
|-----------------------|--------------------------------------|
| <b>Name of entity</b> | <b>SIGMA PHARMACEUTICALS LIMITED</b> |
| <b>ABN</b>            | <b>ABN 15 088 417 403</b>            |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                             |
|----------------------------|-----------------------------|
| <b>Name of Director</b>    | <b>Raymond Mark GUNSTON</b> |
| <b>Date of last notice</b> | 21/09/2012                  |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |   |
|---|---|
| <b>Direct or indirect interest</b>  | Direct interest                         |
| <b>Nature of indirect interest (including registered holder)</b><br>Note: Provide details of the circumstances giving rise to the relevant interest.                        |   |
| <b>Date of change</b>   | 19/12/2012                              |
| <b>No. of securities held prior to change</b>   | 70,230                                  |
| <b>Class</b>  | FPO                                     |
| <b>Number acquired</b>  | 7,084                                   |
| <b>Number disposed</b>  |   |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | \$5,029.64                              |
| <b>No. of securities held after change</b>  | 77,314                                  |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Shares purchased under NED's Share Plan |

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Detail of contract</b>   |  |
| <b>Nature of interest</b>   |  |
| <b>Name of registered holder<br/>(if issued securities)</b>   |  |
| <b>Date of change</b>   |  |
| <b>No. and class of securities to<br/>which interest related prior to<br/>change</b><br><small>Note: Details are only required for a contract in relation<br/>to which the interest has changed</small> |  |
| <b>Interest acquired</b>  |  |
| <b>Interest disposed</b>  |  |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an<br/>estimated valuation</small>   |  |
| <b>Interest after change</b>  |  |

#### Part 3 – <sup>+</sup>Closed period

|   |    |
|---|----|
| <b>Were the interests in the<br/>securities or contracts detailed<br/>above traded during a <sup>+</sup>closed<br/>period where prior written<br/>clearance was required?</b> | No |
| <b>If so, was prior written clearance<br/>provided to allow the trade to<br/>proceed during this period?</b>  |    |
| <b>If prior written clearance was<br/>provided, on what date was this<br/>provided?</b>   |    |

---

<sup>+</sup> See chapter 19 for defined terms.